ADDvise receives allocation decision worth approximately 2.7 MSEK - Regulatory information
ADDvise Group AB's (publ) subsidiary Sonar Oy has received an allocation decision from Oulaskangas Hospital worth approximately 2.7 MSEK regarding X-ray equipment. Delivery of the equipment is planned to take place during Q3 2019.
- We are glad that we through our latest acquisition are strengthening ADDvise’s position on the Finnish market. ADDvise is developing the future healthcare and we are very proud over that says Rikard Akhtarzand, CEO of ADDvise Group.
The appeal time for the allocation decision expires April 17th 2019.
For further information, please contact:
Rikard Akhtarzand, CEO
+46 765-25 90 71
This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on April 3rd 2019, 16:30 CET.
About ADDvise Group
ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com